UNSPSC 51273609: Cocaine muriate

This classification denotes a cns stimulant with the molecular formula C17H21NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XH8T8T6WZH, chemically known as methyl (1r,2r,3s,5s)-3- (benzoyloxy)-8-methyl-8-azabicyclo(3.2.1) octane-2-carboxylate, hydrochloride, but more generally known as cocaine muriate, which bears US NIH Compound Identifier 2826. European Medicines Agency schedules cocaine muriate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13416MIG.

Most nations, for tariff purposes, schedule cocaine muriate under HS 29399110. SMILES: CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)OC(=O)C3CCCCC3)C(=O)OC.CL.

UNSPSC 51273609 Cocaine muriate is a Commodity code that nominally designates a controlled pharmaceutical chemical; however, recent state and local solicitations tagged under this code show no procurement activity for cocaine itself. Instead, issuing bodies are using this code to source harm-reduction and pharmaceutical-supply products: naloxone (an opioid antagonist used in overdose response), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health systems and pharmacy benefit programs. The mismatch between the code's nominal scope and actual buying activity suggests the code is being misapplied or serves as a catch-all placeholder within procurement systems for pharmaceutical-adjacent goods that lack a more precise categorization. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local government facilities.

Recent activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) representing the most substantial recent procurement—an RFP issued January 20, 2026, with a March 26, 2026, response deadline seeking manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC). Seminole County, Florida, issued an IFB (IFB60459723LAS) on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023, response deadline. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed as an exploratory procurement mechanism to inform future formal solicitations. Participation in the MMCAP RFP requires compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and submission of detailed product information including National Drug Codes; evaluation will emphasize price competitiveness (75 percent) alongside compliance, EDI capability, and pricing format options.